<DOC>
	<DOCNO>NCT00243035</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose tipifarnib give together bortezomib see well work treat patient relapsed multiple myeloma . Tipifarnib bortezomib may stop growth cancer cell block enzymes need cell growth . Giving tipifarnib together bortezomib may kill cancer cell .</brief_summary>
	<brief_title>Tipifarnib Bortezomib Treating Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary I . Determine maximum tolerate dose dose-limiting toxicity tipifarnib administer bortezomib patient relapse multiple myeloma . ( Phase I ) II . Determine response rate patient treat regimen . ( Phase II ) III . Determine toxicity profile regimen patient . ( Phase II ) Secondary I . Determine progression-free survival patient treat regimen . ( Phase II ) Tertiary I . Determine whether regimen overcomes CAM-DR primary myeloma cell establish whether ex vivo efficacy predict clinical response patient . II . Determine activate Akt predict clinical resistance level phosphorylated Akt reduce tipifarnib bortezomib patient . III . Determine whether molecular profile primary isolates ( suspension vs adhere ) correlate clinical response patient treat regimen . OUTLINE : This phase I dose-escalation study tipifarnib follow phase II study . Phase I : Patients receive bortezomib IV day 1 , 4 , 8 , 11 oral tipifarnib twice daily day 1-14 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 6 patient treated MTD . Phase II : Patients receive bortezomib phase I tipifarnib phase I MTD . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : Approximately 52-64 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis multiple myeloma Stage II III disease Relapsed disease ≥ 2 prior therapies* , confirm presence 1 following : New lytic lesion A 25 % increase urine serum monoclonal protein Patients receive prior bortezomib must respond therapy Measurable disease , define 1 follow criterion : Serum Mcomponent ≥ 1.0 g/dL serum protein electrophoresis Urine Mprotein excretion &gt; 200 mg per 24hour collection , urine protein electrophoresis Performance status Karnofsky 60100 % More 8 week Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,000/mm^3 Bilirubin ≤ 2 mg/dL Direct bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Creatinine ≤ 1.5 time ULN Calcium ≤ 12 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow study medication Capable follow direction regard study medication , daily caregiver responsible administer study medication No peripheral neuropathy ≥ grade 2 No hypersensitivity follow : Bortezomib Boron Mannitol Imidazole compound ( e.g. , clotrimazole , ketoconazole , miconazole , econazole ) No serious medical psychiatric illness would preclude study compliance No lifethreatening illness ( unrelated tumor ) No active invasive malignancy within past 3 year except nonmelanoma skin cancer No serious infection No prior allogeneic bone marrow transplantation More 30 day since prior concurrent immunotherapy More 30 day since prior concurrent cytotoxic chemotherapy More 14 day since prior highdose corticosteroid No concurrent therapeutic corticosteroid ( e.g. , &gt; 10 mg prednisone per day ) No concurrent hormonal therapy No concurrent antiemetic corticosteroid More 14 day since prior concurrent radiotherapy More 1 year since prior bortezomib More 14 day since prior investigational drug No prior tipifarnib No concurrent cancerrelated treatment No concurrent administration follow enzymeinducing antiepileptic drug : Phenytoin Phenobarbital Carbamazepine No concurrent magnesium aluminumbased antacid within 2 hour tipifarnib administration Concurrent pamidronate bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>